Produced by Mary Caffrey

Posttransplant revumenib maintenance shows promising survival and low relapse in high-risk AML subtypes, with manageable thrombocytopenia; the randomized MenTain trial is underway.

LINKER-AL2 shows linvoseltamab delivers rapid, deep responses in relapsed AL amyloidosis, addressing major unmet need with off-the-shelf access and a manageable safety profile.

The Chief Medical Officer of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and safety in non-Hodgkin lymphoma treatment. This exchange appears in the January issue of Evidence-Based Oncology, the annual recap of the meeting of the American Society of Hematology.

Evidence shows alcohol increases estrogen, raising breast cancer risk, with pandemic-related consumption spikes among women.

The study’s senior author discusses how the combined mechanisms of action produced benefit in progression-free survival.